BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

284 related articles for article (PubMed ID: 32345616)

  • 1. Anti-inflammatory therapy may ameliorate the clinical picture of COVID-19.
    Moutsopoulos HM
    Ann Rheum Dis; 2020 Sep; 79(9):1253-1254. PubMed ID: 32345616
    [No Abstract]   [Full Text] [Related]  

  • 2. After 62 years of regulating immunity, dexamethasone meets COVID-19.
    Cain DW; Cidlowski JA
    Nat Rev Immunol; 2020 Oct; 20(10):587-588. PubMed ID: 32778829
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Covid-19: Time for a paradigm change.
    Buonaguro FM; Ascierto PA; Morse GD; Buonaguro L; Puzanov I; Tornesello ML; Bréchot C; Gallo RC
    Rev Med Virol; 2020 Sep; 30(5):e2134. PubMed ID: 32618072
    [No Abstract]   [Full Text] [Related]  

  • 4. Emerging treatments in COVID-19: Adverse drug reactions including drug hypersensitivities.
    Manjaly Thomas ZR; Leuppi-Taegtmeyer A; Jamiolkowski D; Steveling-Klein E; Bellutti-Enders F; Scherer Hofmeier K; Hartmann K
    J Allergy Clin Immunol; 2020 Oct; 146(4):786-789. PubMed ID: 32710973
    [No Abstract]   [Full Text] [Related]  

  • 5. Treating COVID-19 with colchicine in community healthcare setting.
    Della-Torre E; Della-Torre F; Kusanovic M; Scotti R; Ramirez GA; Dagna L; Tresoldi M
    Clin Immunol; 2020 Aug; 217():108490. PubMed ID: 32492478
    [No Abstract]   [Full Text] [Related]  

  • 6. Leukotrienes, a potential target for Covid-19.
    Citron F; Perelli L; Deem AK; Genovese G; Viale A
    Prostaglandins Leukot Essent Fatty Acids; 2020 Oct; 161():102174. PubMed ID: 32977289
    [No Abstract]   [Full Text] [Related]  

  • 7. Critical COVID-19 disease, homeostasis, and the "surprise" of effective glucocorticoid therapy.
    Chrousos GP; Meduri GU
    Clin Immunol; 2020 Oct; 219():108550. PubMed ID: 32745524
    [No Abstract]   [Full Text] [Related]  

  • 8. Targeting T-cell senescence and cytokine storm with rapamycin to prevent severe progression in COVID-19.
    Omarjee L; Janin A; Perrot F; Laviolle B; Meilhac O; Mahe G
    Clin Immunol; 2020 Jul; 216():108464. PubMed ID: 32405269
    [No Abstract]   [Full Text] [Related]  

  • 9. Immunopathology and immunotherapeutic strategies in severe acute respiratory syndrome coronavirus 2 infection.
    Keam S; Megawati D; Patel SK; Tiwari R; Dhama K; Harapan H
    Rev Med Virol; 2020 Sep; 30(5):e2123. PubMed ID: 32648313
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Confronting the controversy: interleukin-6 and the COVID-19 cytokine storm syndrome.
    Chen LYC; Hoiland RL; Stukas S; Wellington CL; Sekhon MS
    Eur Respir J; 2020 Oct; 56(4):. PubMed ID: 32883678
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Successful use of methylprednisolone for treating severe COVID-19.
    Liu J; Zheng X; Huang Y; Shan H; Huang J
    J Allergy Clin Immunol; 2020 Aug; 146(2):325-327. PubMed ID: 32479759
    [No Abstract]   [Full Text] [Related]  

  • 12. COVID-19: Some clinical questions after the first 4 months.
    Bassetti M; Ansaldi F; Icardi G; Pelosi P; Robba C; Taramasso L; Trucchi C; Vena A; Giacobbe DR
    Eur J Clin Invest; 2020 Jul; 50(7):e13326. PubMed ID: 32562550
    [No Abstract]   [Full Text] [Related]  

  • 13. Leukoerythroblastosis and plasmacytoid lymphocytes in a child with SARS-CoV-2-associated multisystem inflammatory syndrome.
    Lee WS; Margolskee E
    Blood; 2020 Aug; 136(7):914. PubMed ID: 32790856
    [No Abstract]   [Full Text] [Related]  

  • 14. Ivermectin may be a clinically useful anti-inflammatory agent for late-stage COVID-19.
    DiNicolantonio JJ; Barroso J; McCarty M
    Open Heart; 2020 Sep; 7(2):. PubMed ID: 32895293
    [No Abstract]   [Full Text] [Related]  

  • 15. Amelioration of COVID-19-related cytokine storm syndrome: parallels to chimeric antigen receptor-T cell cytokine release syndrome.
    Hoiland RL; Stukas S; Cooper J; Thiara S; Chen LYC; Biggs CM; Hay K; Lee AYY; Shojania K; Abdulla A; Wellington CL; Sekhon MS
    Br J Haematol; 2020 Aug; 190(3):e150-e154. PubMed ID: 32584416
    [No Abstract]   [Full Text] [Related]  

  • 16. Interleukin-6 and severe COVID-19: a systematic review and meta-analysis.
    Mojtabavi H; Saghazadeh A; Rezaei N
    Eur Cytokine Netw; 2020 Jun; 31(2):44-49. PubMed ID: 32933891
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of cytokine signaling by ruxolitinib and implications for COVID-19 treatment.
    Yeleswaram S; Smith P; Burn T; Covington M; Juvekar A; Li Y; Squier P; Langmuir P
    Clin Immunol; 2020 Sep; 218():108517. PubMed ID: 32585295
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunologic Features in Coronavirus Disease 2019: Functional Exhaustion of T Cells and Cytokine Storm.
    Mahmoudi S; Rezaei M; Mansouri N; Marjani M; Mansouri D
    J Clin Immunol; 2020 Oct; 40(7):974-976. PubMed ID: 32648027
    [No Abstract]   [Full Text] [Related]  

  • 19. Lessons from the Italian COVID-19 frontline.
    Bellan M; Sainaghi PP; Gavelli F; Patrucco F; Avanzi GC; Pirisi M; Castello LM
    Minerva Med; 2020 Aug; 111(4):303-305. PubMed ID: 33032392
    [No Abstract]   [Full Text] [Related]  

  • 20. Extracorporeal Hemoadsorption: An Option for COVID-19-Associated Cytokine Storm Syndrome.
    Napp LC; Bauersachs J
    Shock; 2020 Nov; 54(5):700-701. PubMed ID: 32453251
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 15.